Market Place
Sourcing Support
NMPA grants breakthrough therapy designation to Zai Lab’s repotrectinib
31 Aug 2023 //
PHARMACEUTICAL TECHNOLOGY
Ex-Turning Point execs plan to have their next bet, Avenzo
26 May 2023 //
ENDPTS
BMS Completes Acquisition of Turning Point Therapeutics
17 Aug 2022 //
BUSINESSWIRE
Bristol Myers gets necessary clearance for $4.1B Turning Point acquisition
16 Aug 2022 //
ENDPTS
Turning Point of Tampa Opens Drug and Alcohol Detoxification Program
12 Aug 2022 //
GLOBENEWSWIRE
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Turning Point Provides Regulatory Update for Repotrectinib for ROS1+ Adv NSCLC
27 Jul 2022 //
GLOBENEWSWIRE
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
19 Jul 2022 //
BUSINESSWIRE
Petalfast Partners with Turning Point Brands to Expand Distribution of Zig-Zag
28 Jun 2022 //
GLOBENEWSWIRE
Turning Point, MD Anderson Enter Alliance to Advance Precision Cancer Therapies
24 Jun 2022 //
GLOBENEWSWIRE
BMS to acquire cancer drugmaker Turning Point for $4.1bn
04 Jun 2022 //
FT
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
26 May 2022 //
GLOBENEWSWIRE
Turning Point Therapeutics Appoints Steve Sabus as CCO
16 May 2022 //
GLOBENEWSWIRE
Turning Point Therapeutics Granted BTD for Repotrectinib Treatment
10 May 2022 //
GLOBENEWSWIRE
Turning Point Therapeutics Reports First-Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Turning Point Announces Pipeline Expansion, Licensing of TPX-4589
05 May 2022 //
GLOBENEWSWIRE
Turning Point and Zai Lab Announce Topline Analysis for Repotrectinib
28 Apr 2022 //
GLOBENEWSWIRE
Turning Point Shows Positive Topline Data for Repotrectinib in PI/II Study
12 Apr 2022 //
GLOBENEWSWIRE
Turning Point Achieves Enrollment for TRIDENT-1 NTRK +ve TKI-Pretreated Tumor
21 Mar 2022 //
GLOBENEWSWIRE
Turning Point Tx to Participate in Upcoming Investor Conferences
09 Mar 2022 //
GLOBENEWSWIRE
Turning Point to Participate in 42nd Annual Cowen Healthcare Conference - Update
07 Mar 2022 //
GLOBENEWSWIRE
Turning Point Tx to Participate in 42nd Annual Cowen Healthcare Conference
01 Mar 2022 //
GLOBENEWSWIRE
Turning Point Tx Reports Fourth-Quarter and Full Year 2021 Financial Results
28 Feb 2022 //
GLOBENEWSWIRE
FDA Clears Turning Point`s IND for Elzovantinib + Aumolertinib in NSCLC
20 Jan 2022 //
GLOBENEWSWIRE
Turning Point Tx Provides Updates and Anticipated 2022 Pipeline Milestones
18 Jan 2022 //
GLOBENEWSWIRE
Turning Point Presents Early Clinical Data for Repotrectinib From Care Study
23 Oct 2021 //
GLOBENEWSWIRE
Turning Point, EQRx Collaborate to Evaluate Elzovantinib in with Aumolertinib
13 Oct 2021 //
GLOBENEWSWIRE
Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib
11 Oct 2021 //
GLOBENEWSWIRE
Turning Point Presents TRIDENT-1 Study Clinical Data for Repotrectinib
08 Oct 2021 //
GLOBENEWSWIRE
Turning Point Granted Breakthrough Therapy Designation for Repotrectinib
04 Oct 2021 //
GLOBENEWSWIRE
Turning Point Granted Breakthrough Therapy Designation for Repotrectinib
04 Oct 2021 //
GLOBENEWSWIRE
Turning Point Announces Early Clinical Data for Repotrectinib in Solid Tumors
08 Sep 2021 //
GLOBENEWSWIRE
Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study
16 Aug 2021 //
GLOBENEWSWIRE
Turning Point Appoints Paolo Tombesi as Executive VP and Chief Financial Officer
29 Jun 2021 //
GLOBENEWSWIRE
Turning Point Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer
17 Jun 2021 //
GLOBENEWSWIRE
Turning Point Therapeutics Reports First-Quarter Financial Results
05 May 2021 //
GLOBENEWSWIRE
Turning Point Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131
13 Apr 2021 //
GLOBNEWSWIRE
Turning Point Announces New Preclinical Data for Three Drug Candidates
09 Apr 2021 //
GLOBENEWSWIRE
Turning Point to Present New Preclinical Data For Three Drug Candidates
11 Mar 2021 //
GLOBENEWSWIRE
Turning Point Reports Updated Interim Data From Registrational Phase 2 Trident
29 Jan 2021 //
GLOBENEWSWIRE
Turning Point Granted FDA Breakthrough Therapy Designation for Repotrectinib
08 Dec 2020 //
GLOBENEWSWIRE
Turning Point Announces Abstract For TRIDENT-1 Study of Repotrectinib
21 Oct 2020 //
GLOBENEWSWIRE
Turning Point Announces Early Clinical Data For Novel MET Inhibitor TPX-0022
07 Oct 2020 //
GLOBENEWSWIRE
Turning Point Reports Early Interim Data Ph 2 Trident-1 Study Repotrectinib,
19 Aug 2020 //
TPTHERAPEUTICS
Turning Point touts positive pivotal NSCLC data, hints at even faster OK
19 Aug 2020 //
ENDPOINTSNEWS
Turning Point Presents Preclinical Data For Novel RET Candidate, TPX-0046
29 May 2020 //
GLOBENEWSWIRE
Turning Point Announces Initial Clinical Data From Phase 1/2 SWORD-1
05 Apr 2020 //
GLOBENEWSWIRE
Turning Point Therapeutics Names Homa Yeganegi Senior Vice President
06 Jan 2020 //
GLOBE NEWSWIRE
Turning Point shares slide on 82% NSCLC ORR
04 Jun 2019 //
FIERCE BIOTECH
Turning Point tracks an impressive ORR rate in NSCLC
30 May 2019 //
ENDPTS
Turning Point Prices IPO, Raising $166M to Test Cancer Drugs
17 Apr 2019 //
XCONOMY
